Addressing Systemic Racism in Biopharma
How can large pharma improve D&I in its companies?
Understanding the HCP: Patient-Level Data Proves Valuable
Evaluating patient data in the context of complementary information can provide comprehensive market insights for product strategy.
Industry Game Changer: RWE Impacts on Drug Development
COVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.
20th Annual Industry Audit: Year of the Pandemic
Our latest numbers crunch on biopharma financial performance—this one assessing growth and value-generation during the heart of COVID-19—reveals a mix of the familiar and new entrants into the top spots in seven business-critical metrics.
Unconventional collaborations between biopharma and tech are starting to take off.
Defining the Chief Data Officer
While there is broad agreement that the Chief Data Officer plays a critical part in pharma, a definitive description of the role is still evolving.
Leading Through Transition
Imvax CEO John Furey taps into tried-and-true powers of hope and clarity as he moves the clinical stage biotech from single program to platform company.
Biotech Stocks Continue With Underperformance
While Q3 numbers look bleak, is improvement on the horizon?
Could Time Be the Next New Element in Pharma Revenue?
Emerging limits of one-year payer time frames.
Sharing the Science: Pharma’s Content Evolution
How the sharing of scientific content with HCPs is shifting in an era of accelerated digitalization.
Data Science Calls for Shift in Executive Leadership Methods
Soft skills are needed to round out the hard numbers.
A FAB Opportunity Emerging for Europe’s Drugmakers
New EU initiative aims to curve shortage of vaccines and therapies.
Pharm Exec at 40 (2011-2014)
Looking Back at 2011–2014.
Talent & Careers 2022
Examining the incumbent and imminent workforce.
Pharmaceutical Executive, October 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive October 2021 issue in an interactive PDF format.
FDA Caught in Political Crossfire
Critics say FDA is either acting too fast and risking public safety—or too slow, mired in rules while ignoring important scientific findings.
2 Commerce Drive Cranbury, NJ 08512